Ethionamide

Class: Mycolic acid synthesis inhibitor

Details of activity:	Active against Mycobacterium tuberculosis; mycobacterial fatty acid synthesis inhibitor (targets enoyl-ACP reductase)
Description:	Synthetic compound; prodrug of structural analogue of isoniazid; second-line anti-TB drug; undergoes intracellular conversion to active form of drug
Institute where first reported:	Wyeth Pharmaceuticals
Year first mentioned:	1960
Highest developmental phase:	Approved by FDA in 1965
Development status:	Approved

Chemical structure(s):
Canonical SMILES:	CCC1=CC(=CC=N1)C(=S)N
Isomeric SMILES:	CCC1=NC=CC(=C1)C(=S)N
InChI:	InChI=1S/C8H10N2S/c1-2-7-5-6(8(9)11)3-4-10-7/h3-5H,2H2,1H3,(H2,9,11)
InChI Key:	AEOCXXJPGCBFJA-UHFFFAOYSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/2761171

External links:
Guide to Pharmacology:	ethionamide
Main Source:	https://www.microbiologyresearch.org/content/journal/micro/10.1099/00221287-66-3-379